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Abstract
Background: Gestational diabetes mellitus (GDM) exposes mothers and their offspring to short and long-term
complications. The objective of this study was to identify the importance of potentially modifiable predictors of
adverse outcomes in pregnancies with GDM. We also aimed to assess the relationship between maternal predictors
and pregnancy outcomes depending on HbA1c values and to provide a risk stratification for adverse pregnancy
outcomes according to the prepregnancy BMI (Body mass index) and HbA1c at the 1st booking.
Methods: This prospective study included 576 patients with GDM. Predictors were prepregnancy BMI, gestational
weight gain (GWG), excessive weight gain, fasting, 1 and 2-h glucose values after the 75 g oral glucose challenge
test (oGTT), HbA1c at the 1st GDM booking and at the end of pregnancy and maternal treatment requirement.
Maternal and neonatal outcomes such as cesarean section, macrosomia, large and small for gestational age (LGA,
SGA), neonatal hypoglycemia, prematurity, hospitalization in the neonatal unit and Apgar score at 5 min < 7 were
evaluated. Univariate and multivariate regression analyses and probability analyses were performed.
Results: One-hour glucose after oGTT and prepregnancy BMI were correlated with cesarean section. GWG and
HbA1c at the end pregnancy were associated with macrosomia and LGA, while prepregnancy BMI was inversely
associated with SGA. The requirement for maternal treatment was correlated with neonatal hypoglycemia, and
HbA1c at the end of pregnancy with prematurity (all p < 0.05). The correlations between predictors and pregnancy
complications were exclusively observed when HbA1c was ≥5.5% (37 mmol/mol). In women with prepregnancy
BMI ≥ 25 kg/m2 and HbA1c ≥ 5.5% (37 mmol/mol) at the 1st booking, the risk for cesarean section and LGA was
nearly doubled compared to women with BMI with < 25 kg/m2 and HbA1c < 5.5% (37 mmol/mol).
Conclusions: Prepregnancy BMI, GWG, maternal treatment requirement and HbA1c at the end of pregnancy can
predict adverse pregnancy outcomes in women with GDM, particularly when HbA1c is ≥5.5% (37 mmol/mol).
Stratification based on prepregnancy BMI and HbA1c at the 1st booking may allow for future risk-adapted care in
these patients.
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Background
Gestational Diabetes Mellitus (GDM) is defined as dia-
betes first diagnosed in the second or third trimester of
pregnancy that is not preexisting, type 1 or type 2
diabetes [1]. The incidence of GDM has dramatically
increased during the past decades reflecting the on-
going epidemic in obesity and type 2 diabetes [2, 3]. In
Switzerland, using the International Association of
Diabetes and Pregnancy Study Group (IADPSG) Cri-
teria, GDM is diagnosed in 10.9% of pregnancies [4].
GDM exposes the mothers and their offspring to short
and long-term complications [4–7]. Previous studies
have shown the beneficial effect of GDM treatment on
neonatal outcomes such as birth weight and fat, large
for gestational age (LGA) and shoulder dystocia, as well
as maternal outcomes, including cesarean section and
preeclampsia [8, 9].
Several potentially modifiable predictors regarding ad-
verse outcomes have been studied. Maternal overweight
and obesity increase the risk for neonatal complications
[10, 11]. In pregnancies with GDM, gestational weight
gain (GWG) is associated with cesarean section and
LGA [12]. The implementation of the Institute of Medi-
cine guidelines of BMI-based weight gain [13] has also
increased knowledge about the deleterious effect of ex-
cess gestational weight gain (EWG) on neonatal out-
comes [14–16] . Nevertheless, as far as we know, there is
no study evaluating whether GWG or EGW is a more
potent predictor of adverse neonatal outcomes.
Maternal metabolic control affects neonatal birth out-
comes. The correlation between glycated hemoglobin
(HbA1c) at GDM diagnosis and neonatal complications
remains controversial [17–20]. Recent studies have dem-
onstrated the association between third trimester HbA1c
and adverse neonatal outcomes in offspring of treated
women [21, 22]. Few studies have aimed to identify third
trimester HbA1c cutoffs above which neonatal complica-
tions are increased; nevertheless, specific HbA1c cutoffs
are still lacking [22–24]. Maternal glucose values during
the oral glucose tolerance test (oGTT) at 24–28 weeks of
gestational age have been linked to adverse neonatal out-
comes in previous studies [25, 26], although their value
is different in the context of a treated GDM population.
Finally, a recent study in a population with GDM,
demonstrated that there is an association between the
need for medical glucose-lowering treatment and ad-
verse pregnancy outcomes including cesarean section,
LGA, SGA, and prematurity [27]. On the other side, a
recent Atlantic DIP study did not find any difference in
neonatal hypoglycemia rates in women with GDM
treated with insulin vs nutritional care [28]. Further
studies are needed to evaluate whether the risk of neo-
natal hypoglycemia is higher if a maternal medical treat-
ment is required in order to create evidence-based
guidelines for neonatal glucose monitoring or other
adverse outcomes.
The objective of this study was: 1) to identify the re-
spective importance of potentially modifiable predictors
of adverse neonatal and maternal outcomes in the con-
text of a treated population of women with GDM. 2) to
assess the relationship between these predictors and out-
comes depending on HbA1c values. 3) to evaluate the
impact of absolute GWG versus of EGW on these out-
comes. 4) to provide a risk stratification for adverse
pregnancy outcomes depending on prepregnancy Body
Mass Index (BMI) and HbA1c at the 1st booking at the
GDM clinic.
Methods
Study design and patient population
This is a prospective observational study, which included
pregnant women with GDM followed in the Diabetes
and Pregnancy Unit in the Centre Hospitalier Universi-
taire Vaudois (CHUV), Lausanne, Switzerland, between
April 2012 and October 2017.
GDM diagnosis, treatment and follow-up
GDM was diagnosed according to the IADPSG Criteria
[29]. Thus, the diagnosis of GDM was confirmed if fast-
ing blood glucose (FBG) was ≥5.1 mmol/l and/or 1 h
blood glucose was ≥10.0 mmol/l and/or 2 h blood glu-
cose was ≥8.5 mmol/l, following a 75 g oGTT. The treat-
ment was based on the current guidelines of the
American Diabetes Association [30] and of the Endo-
crine Society [31]. At their first clinical appointment, pa-
tients were seen by a nurse specialized in GDM or a
medical doctor, received information on GDM and were
taught how to perform the capillary blood glucose test.
A dietician saw women 1 week later and provided them
with recommendations regarding their GDM, lifestyle
management and weight gain during pregnancy. Women
were encouraged to increase physical activity and had
the possibility to receive physical activity counseling by a
physiotherapist, as well as to participate in GDM phys-
ical activity groups. According to international and local
guidelines (Vaud Cantonal Diabetes Program [32, 33]),
women were asked to control their capillary glucose
values 4 times per day (fasting blood glucose (FBG) in
the morning and 2-h (or 1-h) postprandial blood glucose
after each meal). Additional glucose controls were rec-
ommended on an individual basis, if needed. If despite
lifestyle changes, glucose values remained above targets
two or more times during a 1 to 2-week period (FBG >
5.3 mmol/l, 1-h postprandial glucose > 8 mmol/l and 2-h
postprandial glucose > 7 mmol/l), metformin or insulin
treatment was introduced, depending on glucose values
(i.e. insulin in case of relatively high values), patient
characteristics (i.e BMI) and patient preference. Short
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acting insulin analogues were introduced and adapted to
achieve 1-h postprandial glucose ≤8 mmol/l or 2-h post-
prandial glucose ≤7mmol/l, and long acting insulin ana-
logues to achieve FBG ≤5.3 mmol/l.
Maternal and neonatal anthropometric and metabolic
parameters
Prepregnancy Body Mass index (BMI) was calculated
based on self-reported pre-pregnancy weight or retrieved
from medical charts and measured height on the first
visit at the GDM clinic, using the formula weight (kg)/
[height(m)]2. First booking BMI was calculated based on
the measured weight and height on the first visit at the
GDM clinic. Gestational weight gain was determined as
the difference between the last weight measured before
delivery and pre-pregnancy weight. Excessive gestational
weight gain (EGW) was defined as gestational weight
gain exceeding the thresholds established by the Institute
of Medicine (IOM) Guidelines 2009 for the respective
maternal pre-pregnancy BMI category [13]. HbA1c
levels were measured both on the 1st booking at the
GDM clinic and at the end of pregnancy (last visit before
delivery). HbA1c at the end of pregnancy was only per-
formed after March 2015. Hba1c was measured using a
chemical photometric method (conjugation with boro-
nate; Afinion®). The Afinion® analyzer has shown to have
similar accuracy and precision compared to the high-
performance liquid chromatography (HPLC), which is
IFCC (International Federation of Clinical Chemistry
and Laboratory Medicine) standardized and DCCT (Dia-
betes Control and Complications Trial) aligned [34].
The maternal treatment was documented and classified
in 2 categories (no treatment, treatment with metformin
and/or insulin). Maternal ethnicity was also recorded
and classified in Low (Europe, North America) and High
Risk (Asia, Central and South America, Africa, Oceania)
ethnic groups [30]. Cesarean section was the only mater-
nal complication assessed by this study; the decision for
cesarean section indication was taken by the mother’s
obstetrician.
Neonatal growth parameters such as weight (g) and
length (cm), and head circumference were documented
at birth as an absolute value; percentiles and z-scores for
each of the above mentioned parameters were calculated
using the Intergrowth 21st newborn size application tool
[35]. Large-for-gestational-age was defined as newborn
weight > 90th percentile for sex and gestational age.
Small-for-gestational-age birth weight was defined as
newborn weight < 10th percentile for sex and gestational
age. Macrosomia was defined as birth weight ≥ 4000 g.
Prematurity was defined as gestational age < 37 weeks.
Gestational age was calculated according to the date of
the last menstruations, or as assessed by the fetal ultra-
sound in the cases where gestational age was corrected
during the early in-utero ultrasound evaluation. Accord-
ing to the center protocol, all GDM neonates received
feeding in the first 2 h of life and were fed every 2–3 h
during the first 48 h in order to prevent neonatal
hypoglycemia. Systemic blood glucose monitoring was
conducted according [36] in all newborns the frequency
of the controls (minimum 3) depending on whether the
mother was treated or not with insulin during her preg-
nancy (minimum 8 controls, during 48 h in case of ma-
ternal treatment). Neonatal glycemia was also measured
if symptoms suggested hypoglycemia. Hypoglycemia was
defined as capillary or venous glucose value ≤2.5 mmol/l.
The blood glucose value (capillary or venous) was also
verified in the CHUV central laboratory if capillary
glycemia measured by the glucometer was ≤2.5 mmol/l.
Neonates were hospitalized for intravenous glucose infu-
sion when they presented a symptomatic hypoglycemia,
or a glycemia ≤2.0 mmol/L, or more than one
hypoglycemia ≤2.5 mmol/L despite administration of
additional milk.
Other assessed neonatal complications were stillbirth
or death, Apgar score at 5 min < 7, jaundice requiring
phototherapy and hospitalization in the neonatal unit.
Neonatal data were obtained from the center patient
electronic medical chart for all newborns born in the
CHUV. In the cases where delivery took place in an-
other hospital or clinic, anthropometric parameters at
birth were provided, if possible, by the mother during
her 6–8 weeks post partum visit at the Diabetes and
Pregnancy Unit.
Ethics
Signed informed consent to use maternal and infant data
was obtained from all participating women. Participation
in the study did not interfere with the typical care that
patients receive during pregnancy and after childbirth.
The study was conducted in accordance with the guide-
lines of the declaration of Helsinki, and good clinical
practice. The Human Research Ethics Committee of the
Canton de Vaud approved the study protocol (326/15).
Predictors and outcomes
The predictors in our study included the following
potentially modifiable maternal anthropometric and
metabolic parameters: prepregnancy BMI, GWG and
EWG, fasting, 1-h and 2-h blood glucose values after the
75 g oGTT, HbA1c at the 1st booking after GDM diag-
nosis and at the end of the pregnancy, and maternal
medical treatment requirement. Of note, correlation
between prepregnancy BMI and BMI at the 1st booking
after GDM diagnosis was very high (r = 0.93) and results
unchanged when the latter was used for analysis. The
pregnancy outcomes were all binary variables and
included cesarean section, macrosomia, LGA, SGA,
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hypoglycemia, prematurity, hospitalization in the neo-
natal unit, and Apgar score at 5 min < 7.
Statistical analysis
All data were analyzed using Stata/SE 15.0 (StataCorp
LLC, TX, USA). Normality of continuous variables was
assessed, and normally distributed continuous variables
were described as means and standard deviations (SDs).
Binary outcomes were described as percentages.
Univariate logistic regression analyses, adjusting for
gestational age at birth, neonatal sex and maternal age,
were initially conducted. Due to the small number of
some neonatal complications, analysis was only per-
formed for adverse outcomes present in more than 20
cases [37]. Therefore, the following outcomes were re-
moved from further analysis: 5-min Apgar score < 7,
stillbirth and death.
Maternal predictors of adverse neonatal outcomes
with a p-value < 0.2 in the univariate analysis were
included in the stepwise multiple logistic regression ana-
lysis model. This analysis was also adjusted for gesta-
tional age at birth, neonatal gender and maternal age,
and was conducted in order to identify the maternal
anthropometric and metabolic predictors that are most
significantly associated with adverse neonatal and mater-
nal outcomes. Due to the strong correlation between
HbA1c at the 1st booking and at the end of pregnancy
(r = 0.73), two separate multiple regression models were
selected when these two predictors had a p-value < 0.2
in the univariate analysis for the same outcome. Women
were then divided in 2 groups depending on their
HbA1C value at the 1st booking (HbA1c < 5.5 (37
mmol/mol) and HbA1c ≥ 5.5 (37 mmol/mol)) [38]. The
cutoff value used corresponded to the median HbA1c
value both at the 1st GDM booking and the end of preg-
nancy. Comparisons between the groups were initially
made using the unpaired t-test for continuous variables
and the Fischer’s exact test for binary variables. There-
after, the multiple regression analysis selected above was
performed in both stratified groups. Probability analyses
according to logistic regression models were used to
evaluate the risk of the 2 most frequent outcomes, i.e.
cesarean section and LGA based on 2 correlates that are
routinely and easily available at the 1st GDM booking:
prepregnancy BMI and HbA1c at 1st GDM booking. For
all analyses, adjusted odds ratios (aORs) are reported
along with their 95% confidence intervals (CI), and stat-
istical significance was defined at the two-sided α level
of 0.05, unless specified otherwise.
Results
Study population description
Out of a population of 851 adult women, 111 women
were excluded because they did not provide an informed
consent, 5 due to a known type 1 and 8 due to known
type 2 diabetes. Twelve women were excluded due to a
suspicion of preexistent diabetes, and 9 because they
participated in an intervention clinical trial. Finally, 130
women were excluded due to multiple gestation, missing
newborn sex and/or birth weight. Overall, 576 women
were included in the final analysis.
Baseline maternal characteristics are shown in
Table 1. Mean maternal age was 32.8 ± 5.5 years. Fifty %
of the women were either overweight or obese before
pregnancy. Mean gestational age at GDM diagnosis was
28.6 weeks (SD ± 3.3). Thirty-nine % women were part
of a high-risk ethnic group. Mean gestational weight
gain in the cohort was 12.7 kg (SD ± 6.2), with most of
the weight gain taking place before the 1st booking
(10.3 kg (SD ± 5.6 kg) vs 2.5 (SD ± 2.7 kg) after). Gesta-
tional weight gain exceeded the Institute of Medicine
recommendations in 30% of the patients. Mean HbA1c
value was 5.5% (37 mmol/mol), SD ± 0.4% (5 mmol/
mol) at the 1st booking and 5.6% (38 mmol/mol), SD ±
0.4% (5 mmol/mol) at the end of pregnancy, while me-
dian values were the same at both time points (5.5%
(37 mmol/mol)). A medical treatment was required in
58% of the women; 8% were treated with metformin
only and 50% required insulin (3.3% in combination
with metformin). Cesarean section, including planed
and emergency cesarean section, was performed in 38%
of the population.
Regarding the neonatal characteristics and outcomes
(see Table 1), mean gestational age at birth was 38.9
weeks (SD ± 1.9). Macrosomia was present in 7.8%, LGA
in 16.5% and SGA in 9.4% of newborns. Hypoglycemia
occurred in 10.7% and prematurity in 8.2% of newborns.
Admission in the neonatal unit was required in 11.6% of
cases. Jaundice requiring phototherapy was observed in
3.7% of the neonatal population and 5-min Apgar
score < 7 in 1.7%. Stillbirth was seen in 2 fetuses, of
whom one was excluded from the study due to missing
sex and weight data. One newborn died after birth.
Associations between predictors and neonatal and
maternal outcomes
The results of the univariate and multiple regression
analyses are shown in Table 2 (univariate analyses, only
those with p < 0.2. The integral table with all variables is
shown in Additional file 1: Table S1) and Table 3 (mul-
tiple regression analyses, only those with p < 0.05. The
integral table with all variables is shown in Additional
file 2: Table S2).
We found the following results in the multiple regres-
sion analyses: prepregnancy BMI was positively associ-
ated with cesarean section requirement (p = 0.022) and
inversely with SGA (p = 0.038). Higher GWG was asso-
ciated with macrosomia and LGA (all p ≤ 0.001). The
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1-h oGTT glucose value predicted cesarean section
requirement (p = 0.024), but otherwise there was no
significant association between oGTT values and ad-
verse outcomes. Importantly, HbA1c at the 1st booking
was positively associated with macrosomia, LGA and
the need for cesarean section in the univariate analysis
(all p < 0.05); however, it did not display any significant
associations with neonatal or maternal outcomes in the
multiple regression models. HbA1c at the end of preg-
nancy was also associated with macrosomia, LGA and
prematurity in the multiple regression analyses (all p <
0.05). Finally, maternal treatment requirement was
associated with a two-fold higher risk of neonatal
hypoglycemia (p = 0.032).
No maternal predictor showed a significant association
with hospitalization for neonatal complications and
jaundice requiring phototherapy in the multiple regres-
sion analyses.
HbA1c stratification
Women participating in this study were further strati-
fied in 2 groups, according to the median HbA1c value
at the 1st GDM booking and at the end of pregnancy
(< 5.5% vs ≥5.5% (37 mmol/mol). Regarding maternal
characteristics, there were significant differences in age,
anthropometric and metabolic parameters, high risk
ethnicity, cesarean section and medical treatment
requirement, when stratifying by HbA1c at 1st GDM
booking (See Additional file 3: Table S3). On the other
side, few differences in maternal characteristics were
found when stratifying by the same HbA1c at the end
of pregnancy. Regarding neonatal outcomes, no sign-
ificant differences were observed when stratifying by
HbA1c at the 1st GDM booking, while for HbA1c at
the end of pregnancy macrosomia, prematurity and
jaundice requiring phototherapy were significantly
more prevalent (all p < 0.05).
The results of the multiple regression analyses are
shown in the Table 4. In women with HbA1c ≥ 5.5% (37
mmol/mol) at 1st GDM booking and at the end of preg-
nancy, GWG was associated with more macrosomia and
LGA (all p ≤ 0.03). In women with HbA1c ≥ 5.5% (37
mmol/mol) at the 1st GDM booking, higher prepreg-
nancy BMI was associated with the need for a cesarean
section and higher 1-h oGTT glucose values with pre-
maturity (both p ≤ 0.03). In women with an HbA1c ≥
5.5% (37 mmol/mol) at the end of pregnancy, maternal
medical treatment requirement was associated with
more hypoglycemia (p = 0.020) and less SGA (p = 0.044)
and prepregnancy BMI was also associated with less
SGA (p = 0.028). On the other hand, no association was
found between maternal predictors and neonatal and
maternal complications in the group of women with
HbA1c < 5.5% (37 mmol/mol), neither at the 1st GDM
booking nor at the end of the pregnancy.
Risk stratification at the 1st GDM booking
Finally, probability analyses according to logistic regres-
sion models were performed to provide a risk stratifica-
tion for the 2 most frequent adverse outcomes, i.e.
cesarean section and LGA according to the prepreg-
nancy BMI (< 25 vs ≥ 25 kg/m2) and HbA1c (< 5.5 vs ≥
Table 1 Descriptive maternal and neonatal characteristics
Maternal characteristics
Age (years) 32.8 ± 5.5
Prepregnancy BMI (kg/m2) 26.1 ± 5.4
BMI at the 1st GDM booking (kg/m2) 30 ± 5.5
Gestational weight gain (kg) 12.7 ± 6.2
Gestational weight gain until the 1st GDM booking (kg) 10.3 ± 5.6
Excessive gestational weight gaina n(%) 172 (30)
Fasting oGTT glucose value (mmol/l) 5.2 ± 0.8
1-h oGTT glucose value (mmol/l) 9.6 ± 2.0
2-h oGTT glucose value (mmol/l) 7.8 ± 1.9
Gestational age at the 1st GDM booking (weeks) 28.6 ± 3.3
HbA1c at the 1st GDM booking (%) 5.5 ± 0.4
(mmol/mol) 37 ± 5
Gestational age at the end of pregnancyb (weeks) 35.8 ± 2.9
HbA1c at the end of pregnancyb (%) 5.6 ± 0.4
(mmol/mol) 38 ± 5.0
High risk ethnicity n(%) 219 (39)
Cesarean section n(%) 212 (38)
Maternal medical treatment requirement n(%) 297 (58)
Neonatal characteristics
Gestational age (weeks) 38.9 ± 1.9
Male n(%) 297 (52)
LGAc n(%) 95 (16.5)
SGAd n(%) 54 (9.4)
Macrosomiae n(%) 45 (7.8)
Hypoglycemiaf n(%) 56 (10.7)
Prematurityg n(%) 47 (8.2)
Hospitalization for neonatal complication n(%) 61 (11.6)
Jaundice requiring phototherapy n(%) 21 (3.7)
Apgar 5-min < 7 n(%) 10 (1.7)
Abbreviations: BMI Body mass index, GDM Gestational diabetes mellitus, oGTT
Oral glucose tolerance test, HbA1c Glycated hemoglobin, LGA Large for
gestational age, SGA Small for gestational age
a according to the Institute of Medicine guidelines [13]
b this corresponds to the last visit at the GDM clinic
c LGA: birth weight > 90th percentile for sex and gestational age using the
Intergrowth 21st newborn size application tool [30]
d SGA: birth weight < 10th percentile for sex and gestational age using the
Intergrowth 21st newborn size application tool [30]
e birth weight ≥ 4000 g
f capillary or venous glucose value ≤2.5 mmol/l
g gestational age < 37 weeks
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5.5% (37 mmol/mol)). These predictors can be easily
assessed at the 1st GDM booking (Table 5) and were
significant in the univariate analyses. In the lowest risk
category (BMI < 25 kg/m2 and HbA1c < 5.5%), the
probability for cesarean section was 27% (similar to the
rate of cesarean section in our tertiary hospital (CHUV)
which is 29% [39]) and LGA was 12%, while this risk
was 1.8 times higher (48%) for cesarean section and 1.9
times higher (23%) for LGA in the highest risk
category.
Table 2 Maternal predictors of adverse neonatal and maternal outcomes in univariate analysis
Presence of neonatal and maternal outcomes Maternal predictors Odds Ratio 95% CI P-value
Cesarean section Prepregnancy BMI (kg/m2) 1.06 1.02 1.09 0.001
Excess weight gaina 1.18 1.00 1.38 0.048
1-h oGTT glucose (mmol/l) 1.10 0.99 1.23 0.084
2-h oGTT glucose (mmol/l) 1.08 0.97 1.20 0.166
HbA1c at the 1st GDM booking (%/mmol/mol) 1.63 1.04 2.56 0.033
Maternal medical treatment requirement 1.65 1.11 2.44 0.013
Macrosomiab Gestational weight gain (kg) 1.11 1.05 1.17 < 0.001
Excess weight gain)a 1.41 1.10 1.79 0.006
Fasting oGTT glucose (mmol/l) 1.63 1.16 2.29 0.005
1-h oGTT glucose (mmol/l) 1.17 0.96 1.42 0.115
2-h oGTT glucose (mmol/l) 1.21 0.99 1.47 0.065
HbA1c at the 1st GDM booking (%/mmol/mol) 2.92 1.42 6.03 0.004
HbA1c at the end of pregnancy (%/mmol/mol)c 6.45 1.82 22.90 0.004
Maternal medical treatment requirement 2.75 1.29 5.86 0.009
LGAd Prepregnancy BMI (kg/m2) 1.04 1.00 1.08 0.064
Gestational weight gain (kg) 1.08 1.04 1.12 < 0.001
Excess weight gaina 1.46 1.23 1.74 < 0.001
Fasting oGTT glucose (mmol/l) 1.46 1.12 1.91 0.006
1-h oGGT glucose (mmol/l) 1.13 0.99 1.29 0.077
HbA1c at the 1st GDM booking (%/mmol/mol) 1.84 1.08 3.14 0.025
HbA1c at the end of pregnancy (%/mmol/mol)c 2.84 1.01 7.93 0.047
Maternal medical treatment requirement 1.91 1.14 3.20 0.014
SGAe Prepregnancy BMI (kg/m2) 0.95 0.81 1.00 0.077
Maternal medical treatment requirement 0.59 0.32 1.08 0.087
Hypoglycemiaf Excess weight gaina 1.20 0.96 1.50 0.107
Maternal medical treatment requirement 2.03 1.06 3.88 0.032
Prematurityg Gestational weight gain (kg) 0.97 0.94 1.01 0.159
1-h oGTT glucose (mmol/l) 1.13 0.94 1.36 0.188
HbA1c at the end of pregnancy (%/mmol/mol)c 12.48 1.85 84.13 0.010
Hospitalization for neonatal complication Gestational weight gain (kg) 0.97 0.93 1.00 0.082
Jaundice requiring phototherapy Prepregnancy BMI (kg/m2) 1.08 0.99 1.18 0.071
Excess weight gaina 1.31 0.89 1.95 0.174
Univariate logistic regression analyses adjusted for maternal age, neonatal sex and gestational age. This table shows the odds ratio for the presence (vs absence)
of adverse neonatal and maternal outcomes. Only variables with a p-value of < 0.2 are displayed. See Additional file 1: Table S1 for all results
Abbreviations: CI Confidence interval, BMI Body mass index, GDM Gestational diabetes mellitus, oGTT Oral glucose tolerance test, HbA1c Glycated hemoglobin, LGA
Large for gestational age, SGA Small for gestational age
a according to the Institute of Medicine 2009 guidelines [13]
b birth weight ≥ 4000 g
c this corresponds to the last visit at the GDM clinic
d LGA: birth weight > 90th percentile for sex and gestational age using the Intergrowth 21st newborn size application tool [30]
e SGA: birth weight < 10th percentile for sex and gestational age using the Intergrowth 21st newborn size application tool [30]
f capillary or venous glucose value ≤2.5 mmol/l
g gestational age < 37 weeks
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Discussion
In this study of 576 singleton pregnancies in multi-
ethnic women with GDM, the following potentially
modifiable anthropometric and metabolic parameters
were shown to be important predictors of adverse neo-
natal and/or maternal outcomes (cesarean section,
macrosomia, LGA, SGA, hypoglycemia, prematurity) in
the multiple regression analyses: prepregnancy BMI,
GWG, HbA1c at the end of pregnancy, 1-h oGTT glu-
cose values at GDM diagnosis, and maternal medical
treatment requirement. In the presence of GWG, EWG
was not associated with adverse neonatal outcomes
which hints to the superiority of GWG to predict these
outcomes. In terms of future potential clinical risk strati-
fication, the present study also revealed that in the con-
text of a treated population of women with GDM,
associations between anthropometric and metabolic pa-
rameters and complications are exclusively observed in
women with HbA1c ≥ 5.5% (37 mmol/mol). Another risk
stratification model showed that in women with a pre-
pregnancy BMI of ≥25 kg/m2 and a HbA1c ≥ 5.5% (37
mmol/mol) at the 1st GDM booking, the risk for the
two most frequent adverse outcomes, i.e. cesarean sec-
tion and LGA were around nearly twice as high com-
pared to women with a BMI of < 25 kg/m2 and a
HbA1c < 5.5% (37 mmol/mol).
Prepregnancy BMI was significantly correlated with
the need for cesarean section, which is also consistent
with previous studies [40, 41]. It showed an inverse asso-
ciation with SGA in univariate and multiple regression
analyses, in good agreement with a metanalysis by Goto
et al. and a study by Li et al. [42, 43]. Prepregnancy BMI
was associated with LGA in univariate analyses, but
these associations did not remain significant in the mul-
tiple regression model. This indicates that other corre-
lates, specifically GWG and metabolic control in the
3rd trimester, reflected by the HbA1c at the end of preg-
nancy, may have a more potent influence on fetal
growth. A previous study demonstrated a higher risk for
macrosomia and LGA in overweight and obese patients;
however these studies did not use a multiple regression
model including also the 3rd trimester metabolic control
Table 3 Maternal predictors of adverse neonatal and maternal outcomes in stepwise multiple logistic regression analysis
Odds Ratio 95% CI P-value
Cesarean section
1-h oGTT-glucose (mmol/l) 1.15 1.02 1.29 0.024
Prepregnancy BMI (kg/m2) 1.05 1.01 1.09 0.022
Macrosomiaa
Gestational weight gain (kg) 1.11 1.05 1.19 0.001
HbA1c at the end of pregnancyb (%/mmol/mol) 6.84 1.53 30.54 0.012
LGAc
Gestational weight gain (kg) 1.11 1.06 1.17 < 0.001
HbA1c at the end of pregnancyc (%/mmol/mol) 4.68 1.27 17.28 0.021
SGAd
Prepregnancy BMI (kg/m2) 0.93 0.88 0.99 0.038
Hypoglycemiae
Maternal medical treatment requirement 2.03 1.06 3.88 0.032
Prematurityf
HbA1c at the end of pregnancyc (%/mmol/mol) 22.4 2.36 213.2 0.007
Stepwise multiple logistic regression analyses with all the variables presented in Table 2, adjusted for maternal age, neonatal sex and gestational age. Outcomes
are only shown if at least one predictor is found. Only significant results are displayed (defined significance, P < 0.05, see text). See Additional file 2: Table S2 for
all results
Abbreviations: CI Confidence interval, BMI Body mass index, GDM Gestational diabetes mellitus, oGTT Oral glucose tolerance test, HbA1c Glycated hemoglobin, LGA
Large for gestational age, SGA Small for gestational age
a birth weight ≥ 4000 g
b this corresponds to the last visit at the GDM clinic
c LGA: birth weight > 90th percentile for sex and gestational age using the Intergrowth 21st newborn size application tool [6]
d SGA: birth weight < 10th percentile for sex and gestational age using the Intergrowth 21st newborn size application tool [6]
e capillary or venous glucose value ≤2.5 mmol/l
f gestational age < 37 weeks
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[44]. In accordance with our data, a recent work showed
that maternal overweight and obesity are not independ-
ent determinants of increased birth weight, in contrast
to 3rd trimester glycemic control [21]. Further studies
are necessary to elucidate this observation.
GWG was a significant predictor of LGA and macro-
somia in both univariate and multiple regression ana-
lyses. This is in accordance with previous studies, which
demonstrate a direct association between maternal
weight gain during pregnancy and offspring birthweight
[12, 45–48]. Importantly, in our population most of the
weight was gained before the 1st visit at the GDM clinic
which occurred at a mean of 29 weeks of GA (10.3 ± 5.6
vs 2.5 ± 2.7 kg after). This points out the importance for
GWG monitoring early in pregnancy, as rapid weight
gain in early pregnancy may be associated with the risk
of offspring complications. Although EWG showed a
significant association with LGA and macrosomia in
univariate analyses, these associations did not remain
significant in the multiple regression model, suggesting
that absolute GWG may influence fetal weight gain
more decidedly. EGW was shown to be a significant
predictor of LGA and macrosomia in former studies [14,
44, 49, 50], but these studies did not include GWG in
their model.
In the multiple regression model, the 1-h oGTT glu-
cose value predicted the need for cesarean section.
There were no other significant associations between
oGTT values and neonatal or maternal complications in
this treated population. Similarly, a recent study by Ott
et al., also found that glucose value at oGTT was not
correlated with birth outcomes in treated populations,
with few exceptions [21]. These findings are in contrast
with the large-scale Hyperglycemia and adverse
Table 4 Maternal predictors of neonatal and maternal outcomes in multiple logistic regression analysis stratified by median HbA1c
values
Odds Ratio 95% CI P-value Odds Ratio 95% CI P-value
HbA1c at the 1st GDM booking≥ 5.5% (37
mmol/mol)
HbA1c at the 1st GDM booking < 5.5% (37
mmol/mol)
Cesarean section Prepregnancy BMI (kg/m2) 1.07 1.01 1.15 0.031 1.02 0.96 1.09 0.545
Macrosomiaa Gestational weight gain (kg) 1.19 1.06 1.33 0.003 0.99 0.85 1.14 0.846
LGAb Gestational weight gain (kg) 1.17 1.07 1.30 0.001 0.99 0.88 1.11 0.813
Prematurityd 1-h oGTT glucose value (mmol/l) 1.37 1.03 1.81 0.030 1.10 0.77 1.58 0.590
HbA1c at the end of pregnancy≥ 5.5%
(37 mmol/mol)e
HbA1c at the end of pregnancy < 5.5% (37
mmol/mol)e
Macrosomiaa Gestational weight gain (kg) 1.11 1.02 1.21 0.013 -f -f -f -f
LGAb Gestational weight gain (kg) 1.09 1.02 1.17 0.009 1.25 0.47 3.29 0.658
SGAc Prepregnancy BMI (kg/m2) 0.92 0.86 0.99 0.028 1.06 0.88 1.26 0.547
Maternal medical treatment requirement 0.50 0.26 0.98 0.044 3.26 0.43 24.75 0.254
Hypoglycemiag Maternal medical treatment requirement 2.52 1.16 5.48 0.020 0.95 0.23 3.91 0.944
Multiple logistic regression analyses with all the variables presented in Table 2, adjusted for maternal age, neonatal sex and gestational age. Median HbA1c values
are used for stratification. Predictors are only shown if the P value is < 0.05 in the multiple regression analysis in either stratified group. Outcomes are only shown
if at least one predictor is found
Abbreviations: HbA1c Glycated hemoglobin, CI Confidence interval, GDM Gestational diabetes mellitus, BMI Body mass index, oGTT Oral glucose tolerance test, LGA
Large for gestational age, SGA Small for gestational age
a birth weight ≥ 4000 g
b LGA: birth weight > 90th percentile for sex and gestational age using the Intergrowth 21st newborn size application tool [30]
c SGA: birth weight < 10th percentile for sex and gestational age using the Intergrowth 21st newborn size application tool [30]
d gestational age < 37 weeks
e this corresponds to the last visit at the GDM clinic
f statistical analysis not possible due to the small amount of outcomes
g capillary or venous glucose value ≤2.5 mmol/l
Table 5 Probabilities of future cesarean section and LGA depending on prepregnancy BMI and HbA1c at the 1st GDM booking,
according to logistic regression models
Prepregnancy BMI (kg/m2) HbA1c at the 1st GDM booking (%/ mmol/mol)) Cesarean section LGAa
< 25 < 5.5/37 27% 12%
< 25 ≥ 5.5/37 36% 14%
≥ 25 < 5.5/37 38% 20%
≥ 25 ≥ 5.5/37 48% 23%
Abbreviations: LGA Large for gestational age, BMI Body mass index, HbA1c Glycated hemoglobin, GDM Gestational diabetes mellitus
a birth weight > 90th percentile for sex and gestational age using the Intergrowth 21st newborn size application tool [30]
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pregnancy outcome study (HAPO) study [26] that
showed a continuous association between maternal glu-
cose values at the oGTT and fetal overgrowth in an un-
treated population. The discrepancy in our results may
be due to the treatment’s intensity and efficacy in the
setting of a clinical follow-up.
Moreover, newborns whose mothers required medical
treatment presented hypoglycemia twice as often, des-
pite the rigorous feeding protocol. In contrast, in a re-
cent Atlantic DIP study there was no difference in
hypoglycemia rates in newborns of patients with GDM
treated with insulin vs medical nutritional care [28].
The higher occurrence of neonatal hypoglycemia in the
context of a maternal treatment may imply a worse gly-
cemic control, but also higher variability and glucose
peaks in these patients, which is not always captured by
capillary glycemia and the HbA1c. To the best of our
knowledge, this is a novel observation. A possible bias
in this observation may be linked to the more frequent
glucose monitoring in the newborns whose mothers
required a medical treatment.
In the multiple regression analyses, HbA1c at the 1st
GDM booking did not reveal any association with neo-
natal and maternal outcomes, in good agreement with
previous studies [17, 18, 51, 52]. This finding could be
attributed to the fact that HbA1c reflects the metabolic
control of the preceding weeks to months which is less
relevant at around 29 weeks of gestational age. It is also
explicable to the subsequent treatment’s efficacy and
metabolic control. Nevertheless, HbA1c at 1st GDM
booking was associated with several outcomes in univar-
iate analyses (cesarean section, macrosomia, LGA). Fur-
thermore, when HbA1c at the 1st GDM visit was < 5.5%,
there were no significant correlations between predictors
and adverse outcomes. We also showed that HbA1c is
useful for the stratification of the risk of LGA and
cesarean section at the 1st GDM booking.
By contrast, HbA1c at the end of pregnancy was a
powerful predictor of preterm birth, macrosomia and
LGA in the multiple regression analyses. The HbA1c at
the end of pregnancy value reflects the glycemic control
during the weeks before birth, which is a period of
rapid fetal weight gain. Few studies have evaluated the
correlation between 3rd trimester HbA1c and an-
thropometric parameters as well as neonatal outcomes.
Barquiel et al. showed that 3rd trimester HbA1c > 5%
(31 mmol/mol) increases the risk of LGA and other
neonatal complications [22]. Mikkelsen et al. found that
in women with GDM, HbA1c > 5.6% (38 mmol/mol) is
associated with a threefold increase of LGA and six-
fold increase of neonatal hypoglycemia. Gandhi et al.
demonstrated a higher mean birth weight in newborns
of women with GDM with a 3rd trimester HbA1c >
6.5% (48 mmol/mol) [24]. To the best of our
knowledge, this is the first study that discovered an as-
sociation between HbA1c at the end of pregnancy and
prematurity. Tight 3rd trimester glycemia control
seems to be a key target for avoiding neonatal compli-
cations in pregnancies with GDM.
We conducted a risk stratification model based on the
median HbA1c values at 1st GDM booking and at the
end of pregnancy (cut-off of 5.5% (37 mmol/mol) for
both). Regarding maternal characteristics, there were sig-
nificant differences in anthropometric and metabolic
parameters, high risk ethnicity, medical treatment re-
quirement and cesarean section, when stratifying by
HbA1c at 1st booking (< 5.5% vs ≥5.5% (37 mmol/mol)).
Few differences were found when stratifying by HbA1c
at the end of pregnancy. Regarding neonatal outcomes
no significant differences were observed when stratifying
by HbA1c at the 1st booking, while for HbA1c at the
end of pregnancy macrosomia, prematurity and jaundice
requiring phototherapy were more prevalent when
HbA1c was ≥5.5% (37 mmol/mol) (all p < 0.05). Of note,
achieving an HbA1c of < 5.5% (37 mmol/mol) needed
many lifestyle advices and encouragement and in almost
half of the women (46%) also a medical treatment. We
only have national Swiss data for cesarean section rates
and prematurity: Comparing to these data, cesarean sec-
tion rates in the subgroup with HbA1c < 5.5% (37 mmol/
mol) at the 1st booking, were comparable to the general
population (31% vs 29%), but were higher for the other
subgroups [39]. Prematurity was lower in the subgroup
with HbA1c < 5.5% (37 mmol/mol) at the end of the
pregnancy compared to the general population (1.2% vs
7%) [53]. When comparing to international and mainly
US data, macrosomia and jaundice requiring photother-
apy were even similar in both HbA1c-subgroups [54,
55]. In the subgroup of HbA1c < 5.5% (37 mmol/mol) at
the end of pregnancy, hospitalization for neonatal com-
plications was similar to international data [56, 57].
While it is encouraging to observe that many outcomes
in this treated GDM population are close to the general
population, it is important to note that ethnic and popu-
lation differences as well as differences in the clinical
settings also play a role.
Interestingly, the associations between maternal pre-
dictors and neonatal and maternal outcomes were ex-
clusively seen when HbA1c was ≥5.5% (37 mmol/mol).
This may highlight the need for a more rigorous follow-
up in these women, and a tighter monitoring of their
glucose values. In these women, a repeated HbA1c 1–2
months later could be discussed if capillary glucose
values were normal. In cases where the HbA1c value
remains high despite normal capillary values, continuous
glucose monitoring could be proposed if occasional
peaks or nocturnal glucose elevation are suspected. Fur-
ther studies are necessary to evaluate whether HbA1c
Antoniou et al. BMC Pregnancy and Childbirth          (2019) 19:469 Page 9 of 12
could be used for risk stratification of adverse neonatal
and maternal outcomes in pregnancies complicated with
GDM, and to determine an HbA1c threshold above
which maternal or neonatal follow-up may need to be
intensified.
Finally, we performed probability analyses according
to logistic regression models for risk stratification at the
1st booking based on simple anthropometric and meta-
bolic parameters, such as maternal prepregnancy BMI
and HbA1c at the 1st booking using the two most fre-
quent adverse outcomes (caesarean section and LGA).
In the highest risk category (BMI of ≥25 kg/m2 and a
HbA1c ≥ 5.5% (37 mmol/mol)), the probability was 1.8
times higher and 1.9 times higher for cesarean section
and LGA respectively compared to the lowest category.
We are not aware of other studies providing a risk strati-
fication for these clinically relevant parameters.
The strengths of our study included its prospective
nature, which ensured the presence of complete detailed
information on maternal and neonatal characteristics, as
well as several novel findings in the multiple regression
analyses, the stratified analyses and the probability ana-
lyses. However, several limitations may also be noted.
Firstly, HbA1c is subject to specific pregnancy changes,
shows ethnic variation, and may be affected by condi-
tions such as haemolytic anaemia, chronic renal failure,
severe liver disease and anaemia of chronic disease,
which might influence its validity [58]. HbA1c at the end
of pregnancy was only documented after March 2015,
leading to a smaller sample group for this predictor (n =
201), which nevertheless did not limit its statistical sig-
nificance. However, a higher sample size could have
identified its predictive role for even more outcomes. A
larger population would also have led to a higher num-
ber of rare outcomes and therefore would have ensured
the possibility to include these outcomes in the multi-
variate models. Moreover, the indication for cesarean
section was not specified. Dividing the population in
cesarean section subgroups, such as elective or emer-
gency could be interesting, but would lead to smaller
population sizes and limited statistical power. Another
limitation is that the prepregnancy BMI and the gesta-
tional weight gain were determined using the self-
reported pre-pregnancy weight or data from the medical
charts. A recent review study showed that the magnitude
of error of the self-reported weight is small, and does
not largely bias associations between pregnancy-related
weight and birth outcomes [59]. In our study, prepreg-
nancy BMI and BMI at the 1st booking after GDM diag-
nosis were highly correlated (r = 0.93). Identification of
modifiable factors before GDM diagnosis or even before
pregnancy would be essential to improve maternal and
neonatal outcomes, but unfortunately we only have valid
data for women after the diagnosis of GDM. Another
limitation is that this is an explorative study. Its results
can be used to create new hypotheses.
Conclusions
The present study demonstrated the important role of
simple anthropometric and metabolic maternal predic-
tors on the occurrence of adverse neonatal and maternal
outcomes. We were able to identify several very import-
ant predictors: prepregnancy BMI, GWG, maternal
treatment requirement and HbA1c at the end of preg-
nancy. We also found that predictors were exclusively
associated to adverse neonatal and maternal outcomes
when the HbA1c values were ≥ 5.5% (37 mmol/mol) at
the 1st GDM booking and/or at the end of the preg-
nancy. Risk stratification depending on the maternal pre-
pregnancy BMI and HbA1c at the 1st GDM booking
may allow for risk-adapted care in patients with GDM.
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